Scott W Mueller
Overview
Explore the profile of Scott W Mueller including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
63
Citations
445
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Mueller S, Tran N, Betthauser K, Buckley M, Shupp J, Wiktor A, et al.
J Burn Care Res
. 2024 Dec;
PMID: 39670880
Severe burn injury poses significant clinical challenges, often necessitating the use of vasoactive agents to maintain perfusion. This narrative review explores the current landscape of vasoactive agents in acute burn...
2.
Farrar J, Stefanos S, Cava L, Kiser T, Mueller S, Neumann R, et al.
Ann Pharmacother
. 2024 Aug;
59(3):244-249.
PMID: 39164827
Background: Midazolam (MZ) is commonly used in critically ill neurosurgical patients. Neuro-penetration of MZ and its metabolite, 1-hydroxy-midazolam (1-OH-MZ), is not well characterized. Objective: This study evaluated correlations between serum...
3.
Schwartzman A, Mueller S, Ridgeway K, Balstad B, Wiktor A
J Burn Care Res
. 2024 Mar;
45(4):814-821.
PMID: 38469886
When attempting to deliver specialized rehabilitation therapy interventions, physical therapists (PTs) and occupational therapists (OTs) must account for dynamic and logistical patient factors such as daily wound care, pain, difficulty...
4.
Mueller S, Molina K, Blass B, Gibson C, Kohler A, Krsak M, et al.
J Burn Care Res
. 2024 Feb;
45(3):808-810.
PMID: 38422368
Pyoderma gangrenosum is a rare dermatologic disorder that disrupts the skin barrier, requiring immunosuppressive therapy. We successfully used cefiderocol for the treatment of an extensively drug-resistant Pseudomonas aeruginosa bacteremia, and...
5.
Hill D, Reger M, Todor L, Boyd A, Cogle S, DeWitt A, et al.
J Burn Care Res
. 2024 Jan;
45(3):614-624.
PMID: 38285011
Studies focusing on pharmacotherapy interventions to aid patients after thermal injury are a minor focus in burn injury-centered studies and published across a wide array of journals, which challenges those...
6.
Wang Y, Stroh J, Hripcsak G, Low Wang C, Bennett T, Wrobel J, et al.
J Biomed Inform
. 2023 Nov;
148:104547.
PMID: 37984547
Objective: Computing phenotypes that provide high-fidelity, time-dependent characterizations and yield personalized interpretations is challenging, especially given the complexity of physiological and healthcare systems and clinical data quality. This paper develops...
7.
Mueller S, Blass B, Molina K, Gibson C, Krsak M, Kohler A, et al.
J Burn Care Res
. 2023 Jul;
44(6):1298-1303.
PMID: 37450897
Augmented renal clearance (ARC) is defined by supraphysiologic renal function and is associated with drug failure due to subtherapeutic drug exposure. Burn patients are cited as being at high risk...
8.
Molina K, Mueller S, Miller M, Krsak M
Open Forum Infect Dis
. 2023 May;
10(5):ofad210.
PMID: 37180593
No abstract available.
9.
Stefanos S, Kiser T, MacLaren R, Mueller S, Reynolds P
Pharmacotherapy
. 2023 Mar;
43(4):321-337.
PMID: 36938775
Extravasation is the leakage of intravenous solutions into surrounding tissues, which can be influenced by drug properties, infusion techniques, and patient-related risk factors. Although peripheral administration of vesicants may increase...
10.
Bell C, Rech M, Akuamoah-Boateng K, Kasotakis G, McMurray J, Moses B, et al.
J Pharm Pract
. 2022 Oct;
37(2):351-363.
PMID: 36282867
To evaluate practitioner use of ketamine and identify potential barriers to use in acutely and critically ill patients. To compare characteristics, beliefs, and practices of ketamine frequent users and non-users....